Literature DB >> 26469291

Nephron-sparing surgery across a nation - outcomes from the British Association of Urological Surgeons 2012 national partial nephrectomy audit.

Archie Fernando1,2, Sarah Fowler1, Tim O'Brien1,2.   

Abstract

OBJECTIVE: To determine the scope and outcomes of nephron-sparing surgery (NSS), i.e. partial nephrectomy, across the UK and in so doing set a realistic benchmark and identify fresh contemporary challenges in NSS. PATIENTS AND METHODS: In 2012 reporting of outcomes of all types of nephrectomy became mandatory in the UK. In all, 148 surgeons in 86 centres prospectively entered data on 6 042 nephrectomies undertaken in 2012. This study is a retrospective analysis of the NSS procedures in the dataset.
RESULTS: A total of 1 044 NSS procedures were recorded and the median (range) surgical volume was 4 (1-39) per consultant and 8 (1-59) per centre. In all, 36 surgeons and 10 centres reported on only one NSS. The indications for NSS were: elective with a tumour of ≤4.5 cm in 59%, elective with a tumour of >4.5 cm in 10%, relative in 7%, imperative in 12%, Von Hippel-Lindau in 1%, and unknown in 11%. The median (range) tumour size was 3.4 (0.8-30) cm. The technique used was minimally invasive surgery in 42%, open in 58%, with conversions in 4%. The histology results were: malignant in 80%, benign in 18%, and unknown in 2%. In patients aged <40 years 36% (36/101) had benign histology vs 17% (151/874) of those aged ≥40 years (P < 0.01). In patients with tumours of <2.5 cm 29% (69/238) had benign histology vs 14% (57/410) with tumours of 2.5-4 cm vs 8% (16/194) with tumours of ≥4 cm (P = 0.02). In patients aged <40 years with of tumours of <2.5 cm 44% (15/34) were benign. The 30-day mortality was 0.1% (1/1 044). There were major complications (Clavien-Dindo grade of ≥IIIa) in 5% (53/1 044). There was an increased risk of complications after extended elective NSS of 19% (19/101) vs elective at 12% (76/621) (relative risk [RR] 1.54; P < 0.01). Margins were recorded in 68% (709/1 044) of the patients, with positive margins identified in 7% (51/709). Positive surgical margins after NSS for pathological T3 (pT3) tumours were found in 47.8% (11/23) vs 6.1% (32/523) for pT1a, tumours (RR 5.61; P < 0.01). In all, 14% (894/6 042) of the patients underwent surgery for T1a tumours: 55% (488/894) by NSS, 42% (377/894) by radical nephrectomy (RN), and in 3% (29/894) the procedure used was unknown. Major complications after occurred in 4.9% (24/488) of NSS vs 1.3% (5/377) of RN (P < 0.01). Limitations included poor reporting of renal function data and no data on tumour complexity.
CONCLUSIONS: In its first year, mandatory national reporting has provided several challenging contemporary insights into NSS.
© 2015 The Authors BJU International © 2015 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  complications; national audit; nephron‐sparing surgery; partial nephrectomy; renal cancer

Mesh:

Year:  2015        PMID: 26469291     DOI: 10.1111/bju.13353

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  Organ-sparing procedures in GU cancer: part 1-organ-sparing procedures in renal and adrenal tumors: a systematic review.

Authors:  Raouf Seyam; Mahmoud I Khalil; Mohamed H Kamel; Waleed M Altaweel; Rodney Davis; Nabil K Bissada
Journal:  Int Urol Nephrol       Date:  2019-01-08       Impact factor: 2.370

2.  Image-guided biopsy of small (≤4 cm) renal masses: the effect of size and anatomical location on biopsy success rate and complications.

Authors:  Matthew J Seager; Uday Patel; Christopher J Anderson; Michael Gonsalves
Journal:  Br J Radiol       Date:  2018-02-22       Impact factor: 3.039

Review 3.  Renal cryoablation - a practical guide for interventional radiologists.

Authors:  Matthew Seager; Shankar Kumar; Emma Lim; Graham Munneke; Steve Bandula; Miles Walkden
Journal:  Br J Radiol       Date:  2020-09-22       Impact factor: 3.039

4.  Robotic-assisted partial nephrectomy (RAPN) and standardization of outcome reporting: a prospective, observational study on reaching the "Trifecta and Pentafecta".

Authors:  D Sri; R Thakkar; H R H Patel; J Lazarus; F Berger; R McArthur; H Lavigueur-Blouin; M Afshar; C Fraser-Taylor; P Le Roux; J Liban; C J Anderson
Journal:  J Robot Surg       Date:  2020-09-03

5.  Surgical treatment of kidney tumors - contemporary trends in clinical practice.

Authors:  Milan Hora; Viktor Eret; Ivan Trávníček; Kristýna Procházková; Tomáš Pitra; Olga Dolejšová; Ondřej Hes; Fredrik Petersson
Journal:  Cent European J Urol       Date:  2016-09-22

6.  Factors associated with postoperative renal sinus invasion and perinephric fat invasion in renal cell cancer: treatment planning implications.

Authors:  Dong Ni; Xin Ma; Hong-Zhao Li; Yu Gao; Xin-Tao Li; Yu Zhang; Qing Ai; Qing-Bo Huang; Jun-Yao Duan; Xu Zhang
Journal:  Oncotarget       Date:  2017-12-15

7.  Protocol for a feasibility study of a cohort embedded randomised controlled trial comparing NEphron Sparing Treatment (NEST) for small renal masses.

Authors:  Joana B Neves; David Cullen; Lee Grant; Miles Walkden; Steve Bandula; Prasad Patki; Ravi Barod; Faiz Mumtaz; Michael Aitchison; Elena Pizzo; Veronica Ranieri; Norman Williams; William Wildgoose; Kurinchi Gurusamy; Mark Emberton; Axel Bex; Maxine G B Tran
Journal:  BMJ Open       Date:  2019-06-11       Impact factor: 2.692

8.  Open Partial Nephrectomy with Zero Ischaemia Using a Supra 12th Rib Miniflank Incision: A Minimally Invasive Open Approach for Small Renal Masses.

Authors:  Syed Ali Ehsanullah; Abida Sultana; Brian Kelly; Charlotte Dunford; Zaheer Shah
Journal:  Adv Urol       Date:  2021-12-31

9.  Real world outcomes of biopsy-proven oncocytic neoplasm of the kidney managed by surveillance.

Authors:  Flora E Rodger; Keiran Brown; Steve Leung; Jack Coode-Bate; James Armitage; Anne Warren; Jane Hendry; Grant D Stewart; Alex Laird; Grenville M Oades
Journal:  BJUI Compass       Date:  2022-03-03

10.  Trends in the surgical management of renal cell carcinoma in a contemporary tertiary care setting.

Authors:  Noor Nabi Junejo; Sultan Saud Alkhateeb; Majed Faisal Alrumayyan; Khalid Yusuf Alkhatib; Hassan Messfer Alzahrani; Mohammed Faihan Alotaibi; Khalid Ibrahim Alothman; Turki Omar Al-Hussain; Waleed Mohamed Altaweel
Journal:  Urol Ann       Date:  2021-03-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.